Stellari Fabio, Sala Angelo, Ruscitti Francesca, Carnini Chiara, Mirandola Prisco, Vitale Marco, Civelli Maurizio, Villetti Gino
Chiesi Farmaceutici S.p.A, Parma, Italy.
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milan, Italy.
J Transl Med. 2015 Oct 24;13:336. doi: 10.1186/s12967-015-0696-5.
Asthma is a multifactorial disease for which a variety of mouse models have been developed. A major drawback of these models is represented by the transient nature of the airway pathology peaking 24-72 h after challenge and resolving in 1-2 weeks. We characterized the temporal evolution of pulmonary inflammation and tissue remodeling in a recently described mouse model of chronic asthma (8 week treatment with 3 allergens: Dust mite, Ragweed, and Aspergillus; DRA).
We studied the DRA model taking advantage of fluorescence molecular tomography (FMT) imaging using near-infrared probes to non-invasively evaluate lung inflammation and airway remodeling. At 4, 6, 8 or 11 weeks, cathepsin- and metalloproteinase-dependent fluorescence was evaluated in vivo. A subgroup of animals, after 4 weeks of DRA, was treated with Budesonide (100 µg/kg intranasally) daily for 4 weeks.
Cathepsin-dependent fluorescence in DRA-sensitized mice resulted significantly increased at 6 and 8 weeks, and was markedly inhibited by budesonide. This fluorescent signal well correlated with ex vivo analysis such as bronchoalveolar lavage eosinophils and pulmonary inflammatory cell infiltration. Metalloproteinase-dependent fluorescence was significantly increased at 8 and 11 weeks, nicely correlated with collagen deposition, as evaluated histologically by Masson's Trichrome staining, and airway epithelium hypertrophy, and was only partly inhibited by budesonide.
FMT proved suitable for longitudinal studies to evaluate asthma progression, showing that cathepsin activity could be used to monitor inflammatory cell infiltration while metalloproteinase activity parallels airway remodeling, allowing the determination of steroid treatment efficacy in a chronic asthma model in mice.
哮喘是一种多因素疾病,为此已开发出多种小鼠模型。这些模型的一个主要缺点是气道病理的短暂性,在激发后24 - 72小时达到峰值,并在1 - 2周内消退。我们在最近描述的慢性哮喘小鼠模型(用三种变应原:尘螨、豚草和曲霉菌进行8周治疗;DRA)中对肺部炎症和组织重塑的时间演变进行了表征。
我们利用荧光分子断层扫描(FMT)成像,使用近红外探针来非侵入性评估肺部炎症和气道重塑,对DRA模型进行了研究。在第4、6、8或11周,在体内评估组织蛋白酶和金属蛋白酶依赖性荧光。一组动物在DRA治疗4周后,每天鼻内给予布地奈德(100μg/kg),持续4周。
DRA致敏小鼠中组织蛋白酶依赖性荧光在第6周和第8周显著增加,并被布地奈德明显抑制。这种荧光信号与支气管肺泡灌洗嗜酸性粒细胞和肺部炎性细胞浸润等体外分析结果密切相关。金属蛋白酶依赖性荧光在第8周和第11周显著增加,与通过Masson三色染色组织学评估的胶原沉积以及气道上皮肥大密切相关,并且仅被布地奈德部分抑制。
FMT被证明适用于评估哮喘进展的纵向研究,表明组织蛋白酶活性可用于监测炎性细胞浸润,而金属蛋白酶活性与气道重塑平行,从而能够确定小鼠慢性哮喘模型中类固醇治疗的疗效。